Lamivudine/zidovudine/abacavir

Drug Profile

Lamivudine/zidovudine/abacavir

Alternative Names: Abacavir/lamivudine/zidovudine; Abacavir/zidovudine/lamivudine; Lamivudine/abacavir/zidovudine; Trizivir; Zidovudine/abacavir/lamivudine; Zidovudine/lamivudine/abacavir

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiretrovirals; Azides; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV replication inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 18 Dec 2013 First generic equivalent launched in the US for HIV-1 infections (alone or in combination with other antiretrovirals)
  • 10 Dec 2013 First generic equivalent approved in US for HIV-1 infections (alone or in combination with other antiretrovirals)
  • 19 May 2005 Trizivir® has received traditional approval for the treatment of HIV infection in the USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top